Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070692 · ClinicalTrials.gov registry record · Phase 4
Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
A Phase 4 study of Menstruation Disturbances, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT02070692: Completed Phase 4 study of Menstruation Disturbances, sponsored by Oregon Health and Science University.
NCT02070692 is a Phase 4 study of Menstruation Disturbances that has completed, run by Oregon Health and Science University. The registered enrollment target is 56 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02070692, a Phase 4 study of Menstruation Disturbances, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.
Primary Outcome
The primary objective of this study is to determine whether tamoxifen taken by users of the ENG implant on an as-needed basis for frequent or prolonged bleeding can reduce the number of bleeding days by at least 40% over 180 days, when compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tamoxifen
Study Locations (1)
Oregon
- Oregon Health & Science University (OHSU) - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
What the finished NCT02070692 record still lists
NCT02070692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Menstruation Disturbances appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02070692 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02070692 about?
NCT02070692 is a clinical study titled "Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users". The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.
What is the current status of trial NCT02070692?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2014-02. Estimated completion is 2015-12.
What conditions does trial NCT02070692 study?
This clinical trial studies the following conditions: Menstruation Disturbances.
What interventions are being tested in trial NCT02070692?
The interventions under investigation include: Placebo (DRUG), Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT02070692?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02070692 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menstruation Disturbances
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02070692's enrollment target sits among peer trials
56 1213th of 2000 higher than 783 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia